Literature DB >> 27528066

Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.

Tanja Dudenbostel1, Lama Ghazi2, Mingchun Liu2, Peng Li2, Suzanne Oparil2, David A Calhoun2.   

Abstract

Prospective studies indicate that hyperaldosteronism is found in 20% of patients with resistant hypertension. A small number of observational studies in normotensive and hypertensive patients suggest a correlation between aldosterone levels and obesity while others could not confirm these findings. The correlation between aldosterone levels and body mass index (BMI) in patients with resistant hypertension has not been previously investigated. Our objective was to determine whether BMI is positively correlated with plasma aldosterone concentration, plasma renin activity, aldosterone:renin ratio, and 24-hour urinary aldosterone in black and white patients. We performed a cross-sectional analysis of a large diverse cohort (n=2170) with resistant hypertension. The relationship between plasma aldosterone concentration, plasma renin activity, aldosterone:renin ratio, 24-hour urinary aldosterone, and BMI was investigated for the entire cohort, by sex and race (65.3% white, 40.3% men). We demonstrate that plasma aldosterone concentration and aldosterone:renin ratio were significantly correlated to BMI (P<0.0001) across the first 3 quartiles, but not from the 3rd to 4th quartile of BMI. Plasma renin activity was not correlated with BMI. Twenty-four-hour urinary aldosterone was positively correlated across all quartiles of BMI for the cohort (P<0.0001) and when analyzed by sex (men P<0.0001; women P=0.0013) and race (P<0.05), and stronger for men compared with women (r=0.19, P<0.001 versus r=0.05, P=0.431, P=0.028) regardless of race. In both black and white patients, aldosterone levels were positively correlated to increasing BMI, with the correlation being more pronounced in black and white men. These findings suggest that obesity, particularly the abdominal obesity typical of men, contributes to excess aldosterone in patients with resistant hypertension.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  association; body mass index; body weight; hypertension; obesity

Mesh:

Substances:

Year:  2016        PMID: 27528066      PMCID: PMC5016255          DOI: 10.1161/HYPERTENSIONAHA.116.07806

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  65 in total

1.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  Simultaneous measurement of aldosterone and cortisol by high-performance liquid chromatography-tandem mass spectrometry: application to dehydration-rehydration studies.

Authors:  Paul J Taylor; Simon P van Rosendal; Jeff S Coombes; Richard D Gordon; Michael Stowasser
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-03-23       Impact factor: 3.205

3.  Insulin, renin-aldosterone system and blood pressure in obese people.

Authors:  G Andronico; S Cottone; M T Mangano; R Ferraro-Mortellaro; G Baiardi; N Grassi; L Ferrara; G Mulé; G Cerasola
Journal:  Int J Obes Relat Metab Disord       Date:  2001-02

4.  Role for aldosterone in blood pressure regulation of obese adolescents.

Authors:  A P Rocchini; V L Katch; R Grekin; C Moorehead; J Anderson
Journal:  Am J Cardiol       Date:  1986-03-01       Impact factor: 2.778

5.  High prevalence of unrecognized sleep apnoea in drug-resistant hypertension.

Authors:  A G Logan; S M Perlikowski; A Mente; A Tisler; R Tkacova; M Niroumand; R S Leung; T D Bradley
Journal:  J Hypertens       Date:  2001-12       Impact factor: 4.844

6.  Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension.

Authors:  Monique N Pratt-Ubunama; Mari K Nishizaka; Robyn L Boedefeld; Stacey S Cofield; Susan M Harding; David A Calhoun
Journal:  Chest       Date:  2007-02       Impact factor: 9.410

7.  Low-Dose Mineralocorticoid Receptor Blockade Prevents Western Diet-Induced Arterial Stiffening in Female Mice.

Authors:  Vincent G DeMarco; Javad Habibi; Guanghong Jia; Annayya R Aroor; Francisco I Ramirez-Perez; Luis A Martinez-Lemus; Shawn B Bender; Mona Garro; Melvin R Hayden; Zhe Sun; Gerald A Meininger; Camila Manrique; Adam Whaley-Connell; James R Sowers
Journal:  Hypertension       Date:  2015-05-26       Impact factor: 10.190

8.  A novel adipokine CTRP1 stimulates aldosterone production.

Authors:  Jun Ho Jeon; Kun-yong Kim; Jae Hyeong Kim; Ahmi Baek; Hyungin Cho; Young Ho Lee; Jong Wan Kim; Dohee Kim; Seung Hyun Han; Jong-Seok Lim; Keun Il Kim; Do Young Yoon; Soo-Hyun Kim; Goo Taeg Oh; Eunjoon Kim; Young Yang
Journal:  FASEB J       Date:  2008-01-02       Impact factor: 5.191

9.  Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion.

Authors:  Theodore L Goodfriend; Dennis L Ball; Brent M Egan; William B Campbell; Kasem Nithipatikom
Journal:  Hypertension       Date:  2004-01-12       Impact factor: 10.190

10.  Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity.

Authors:  C Dall'Asta; P Vedani; P Manunta; P Pizzocri; M Marchi; M Paganelli; F Folli; A E Pontiroli
Journal:  Nutr Metab Cardiovasc Dis       Date:  2008-08-20       Impact factor: 4.222

View more
  18 in total

1.  Controlling Hypertension: We Have the Tools-We Just Need to Use Them.

Authors:  David J Hyman; Valory Pavlik
Journal:  J Gen Intern Med       Date:  2017-08       Impact factor: 5.128

Review 2.  Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension.

Authors:  Tanja Dudenbostel; David A Calhoun
Journal:  Am J Hypertens       Date:  2016-09-08       Impact factor: 2.689

Review 3.  Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women.

Authors:  Rohan Samson; Andrea Qi; Abhishek Jaiswal; Thierry H Le Jemtel; Suzanne Oparil
Journal:  Curr Hypertens Rep       Date:  2017-05       Impact factor: 5.369

Review 4.  Treatment of Resistant and Refractory Hypertension.

Authors:  Maria Czarina Acelajado; Zachary H Hughes; Suzanne Oparil; David A Calhoun
Journal:  Circ Res       Date:  2019-03-29       Impact factor: 17.367

5.  Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant.

Authors:  Lama Ghazi; Suzanne Oparil; David A Calhoun; Chee Paul Lin; Tanja Dudenbostel
Journal:  Hypertension       Date:  2017-03-27       Impact factor: 10.190

Review 6.  The mineralocorticoid receptor-an emerging player in metabolic syndrome?

Authors:  Moe Thuzar; Michael Stowasser
Journal:  J Hum Hypertens       Date:  2021-02-01       Impact factor: 3.012

7.  The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study.

Authors:  Jenifer M Brown; Mohammed Siddiqui; David A Calhoun; Robert M Carey; Paul N Hopkins; Gordon H Williams; Anand Vaidya
Journal:  Ann Intern Med       Date:  2020-05-26       Impact factor: 25.391

8.  Relationship between body mass index, cardiovascular biomarkers and incident heart failure.

Authors:  Navin Suthahar; Laura M G Meems; Dion Groothof; Stephan J L Bakker; Ron T Gansevoort; Dirk J van Veldhuisen; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2021-02-08       Impact factor: 15.534

9.  Frequency & factors associated with apparent resistant hypertension among Ghanaians in a multicenter study.

Authors:  Nana Kwame Ayisi-Boateng; Aliyu Mohammed; Douglas Aninng Opoku; Fred Stephen Sarfo
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-20       Impact factor: 3.738

10.  Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.

Authors:  Valentina Cannone; Alessia Buglioni; S Jeson Sangaralingham; Christopher Scott; Kent R Bailey; Richard Rodeheffer; Margaret M Redfield; Riccardo Sarzani; John C Burnett
Journal:  Mayo Clin Proc       Date:  2018-08       Impact factor: 11.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.